QTc prolongation during antiviral therapy in two COVID-19 patients.
J Clin Pharm Ther
; 45(5): 1190-1193, 2020 Oct.
Article
in English
| MEDLINE | ID: covidwho-672051
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE:
Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19). CASE DESCRIPTION We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients. WHAT IS NEW ANDCONCLUSION:
Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Long QT Syndrome
/
Ritonavir
/
Lopinavir
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Prognostic study
Limits:
Female
/
Humans
/
Middle aged
Language:
English
Journal:
J Clin Pharm Ther
Journal subject:
Pharmacy
/
Therapeutics
Year:
2020
Document Type:
Article
Affiliation country:
Jcpt.13183
Similar
MEDLINE
...
LILACS
LIS